ERBB2 and breast cancer: This finding is also consistent with the well-known fact that BC subtypes respond differentially to NAC [26], and that the prognostic value of pCR is greatest in aggressive tumor subtypes such as TNBC or HER2-positive BC [1, 27] than in luminal BCs.